Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02471846 · ClinicalTrials.gov registry record · Phase 1
A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
NCT02471846 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 158 participants.
The verdict
NCT02471846, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of GDC-0919 and atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy or for which standard therapy is ineffective, intolerable, or inappropriate. Participants will be enrolled in two stages, including a dose-escalation stage and an expansion stage.
Interventions
- DRUG Atezolizumab
- DRUG GDC-0919
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2015-07-28 |
| Est. Completion | 2019-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02471846
The ClinicalTrials.gov registry entry for NCT02471846 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT02471846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02471846 about?
NCT02471846 is a clinical study titled "A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors". This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of GDC-0919 and atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy or for which standard therapy is ine...
What is the current status of trial NCT02471846?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2015-07-28. Estimated completion is 2019-10-02.
What interventions are being tested in trial NCT02471846?
The interventions under investigation include: Atezolizumab (DRUG), GDC-0919 (DRUG).
Who is sponsoring clinical trial NCT02471846?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.